Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2018-01-16 |
Foundation Medicine (USA - MA) Pfizer (USA - NY) |
companion diagnostics (CDx) that will be included in updates to FoundationOne CDx™. FoundationOne CDx is Foundation Medicine's FDA-approved comprehensive genomic profiling (CGP) assay for all solid tumors that incorporates multiple companion diagnostics. |
|
|
Cancer - Oncology |
Collaboration agreement |
2018-01-15 |
Avacta (UK) Glythera (UK) |
highly targeted bio-therapeutics |
|
collaboration |
Technology - Services |
Licensing agreement |
2018-01-11 |
Boehringer Ingelheim (Germany) Pharmaxis (Australia) |
PXS4728A/BI 1467335 |
NASH (non-alcoholic steatohepatitis) chronic obstructive pulmonary disease (COPD) |
licensing - development - production - manufacturing - commercialisation |
Liver diseases - Hepatic diseases - Inflammatory diseases - Pulmonary diseases - Respiratory diseases |
Milestone |
2018-01-10 |
Ipsen (France) |
vice-president |
|
nomination |
Cancer - Oncology - Rare diseases - Neurological diseases |
Nomination |
2018-01-10 |
Aimmune Therapeutics (USA - CA) Archer Daniels Midland (USA -IL) |
peanuts and tree nuts and exclusively supplies the starting material for AR101 |
peanut allergy |
production - manufacturing
|
Allergic diseases |
Production agreement |
2018-01-10 |
Basilea Pharmaceutica (Switzerland) Pfizer (USA - NY) |
Cresemba® (isavuconazole) |
life-threatening invasive mold infections |
licensing |
Infectious diseases |
Licensing agreement |
2018-01-09 |
BeiGene (China) Boehringer Ingelheim (Germany) |
tislelizumab (BGB-A317) |
|
production - manufacturing |
Technology - Services |
Production agreement |
2018-01-08 |
Sanofi (France) Regeneron Pharmaceuticals (USA - NY) |
bispecific antibodies and monoclonal antibodies including REGN3500, dupilumab and programmed cell death protein 1 (PD-1) inhibitor cemiplimab |
|
collaboration - development - commercialisation |
Allergic diseases - Cancer - Oncology |
Collaboration agreement |
2018-01-08 |
Five Prime Therapeutics (USA - CA) BMS (USA - NY) |
immuno-oncology therapies directed toward targets in three undisclosed immune checkpoint pathways |
|
R&D - development - commercialisation |
Cancer - Oncology |
Milestone |
2018-01-08 |
GSK (UK) Regeneron Pharmaceuticals (USA - NY) UK Biobank (UK) IBM Watson Health (USA) Abbvie (USA - IL) Alnylam Pharmaceuticals (USA - MA) AstraZEneca (UK) Biogen (USA - MA) Pfizer (USA - NY) |
genetic exome sequence data |
|
collaboration - research |
Technology - Services |
Collaboration agreement |
2018-01-08 |
Innate Pharma (France) |
chief scientific officer |
|
nomination |
Cancer - Oncology - Immunological diseases |
Nomination |
2018-01-08 |
Heidelberg Pharma (Germany) Advanced Proteome Therapeutics (Canada) |
antibody-drug conjugates (ADCs) |
|
collaboration |
Cancer - Oncology |
Milestone |
2018-01-08 |
Adaptimmune (UK) Cell and Gene Therapy Catapult (UK) |
SPEAR T-cell therapies |
|
production - manufacturing |
Technology - Services |
Production agreement |
2018-01-08 |
Bioaster (France) Sanofi Pasteur (France) |
MOSAIC (MOlecular Signatures of Adjuvanted vaccIne
Candidates) project |
|
collaboration - research |
Infectious diseases |
Collaboration agreement |
2018-01-08 |
BeiGene (China) Mirati Therapeutics (USA - CA) |
sitravatinib |
non-small cell lung cancer (NSCLC) |
licensing - development - production - commercialisation |
Cancer - Oncology |
Licensing agreement |
2018-01-07 |
Genzyme (USA - MA), a Sanofi company (France) - Alnylam Pharmaceuticals (USA - MA) |
RNAi therapeutics including ALN-AT3, fitusiran, patisiran and ALN-TTRsc02 |
rare genetic diseases including hemophilia A, hemophilia B |
development - commercialisation |
Rare diseases - Genetic diseases |
Development agreement |
2018-01-05 |
Takeda Pharmaceutical (Japan) Denali Therapeutics (USA - CA) |
up to three specified therapeutic product candidates for neurodegenerative diseases |
neurodegenerative disorders, including Alzheimer’s disease and other indications |
collaboration - development - commercialisation |
Neurodegenerative diseases |
Development agreement |
2018-01-05 |
Aduro Biotech (USA - CA) |
chief financial officer |
|
nomination |
Cancer - Oncology |
Nomination |
2018-01-05 |
Peregrine Pharmaceuticals, now Avid Bioservices (USA - CA) |
|
|
restructuring |
Technology - Services |
Restructuring |
2018-01-05 |
Retrotophin (USA - CA) Censa Pharmaceuticals (USA - MA) |
CNSA-001 |
phenylketonuria |
development |
Rare diseases - Genetic diseases - Metabolic diseases |
Development agreement |